David Moss from Lipoxen plc in the United Kingdom aims to develop a non-live polio vaccine using liposomes to entrap and deliver defined poliovirus antigens effectively to the immune system. If successful, the project will expedite the development and global deployment of a simple, economic new polio vaccine.
Grant ID
OPP1036175
Show on Hub
On
Show on Spoke
On
Follow-on Funding
Off
Lead Funding Organization
Challenge
Initiatives
Principal Investigator
Award Manager
Individual Funder Information
Funding Organization
Funding Amount (in original currency)
100000.00
Funding Currency
USD
Funding Amount (in USD)
100000.00
Project Type
Project Primary Sector
Project Subsector
Funding Date Range
-
Funding Total (In US dollars)
100000.00
Co-Funded
False